RxDoctor Payments Data

Sun Kim, MD

Urology · San Bernardino, CANPI 1093738932

Payments from drug & device makers

$47,806in general payments, 2019–2025

Across 377 payments — averaging $126.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$29K
  • Neotract Inc.$6K
  • Intuitive Surgical$3K
  • Johnson & Johnson$2K
  • AbbVie$1K
  • Teleflex LLC$1K
  • plus $4K from 46 others

What the payments were for

  • Consulting fees$7584%
  • Speaking & faculty fees$4,70026%
  • Travel & lodging$9315%
  • Food & beverage$8,60947%
  • Education$3,31118%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,806 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$514,776
Medicare patients
1,057
Services billed
4,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lupron DepotLeuprolide Acetate88$456,992
MyrbetriqMirabegron571$422,106
GemtesaVibegron147$116,769
TrelstarTriptorelin Pamoate49$105,256
OrgovyxRelugolix16$43,109
Tamsulosin Hcl2,130$24,940
Finasteride1,763$20,419
EligardLeuprolide Acetate15$19,569
Oxybutynin Chloride ErOxybutynin Chloride505$12,325
Mirabegron ErMirabegron12$9,670
Cephalexin282$5,538
Solifenacin Succinate44$4,833
Tadalafil20$4,002
Doxazosin Mesylate261$3,426
Testosterone13$3,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLupron Depot$1,306$456,99288 claims
Astellas Pharma US IncMyrbetriq$391$422,106571 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$222$159,878163 claims
Verity Pharmaceuticals Inc.Trelstar$283$105,25649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.

Other urology in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →